Xenon Pharmaceuticals Reports Q4/FY25 Results, Secures $242M via ATM, and Anticipates Key Phase 3 Data in March

summarizeSummary

Xenon Pharmaceuticals reported Q4 and full-year 2025 financial results, detailing increased R&D spend and net loss, while announcing a successful $242.2 million capital raise via ATM sales that extends its cash runway into H2 2027, and confirming imminent Phase 3 X-TOLE2 data in March 2026.

check_boxKey Events

• Q4 and Full Year 2025 Financial Results

  Reported increased R&D expenses of $300.9 million for 2025 (up from $210.4 million in 2024) and a net loss of $345.9 million for 2025 (up from $234.3 million in 2024), reflecting significant investment in clinical development.

• Significant Capital Raise via ATM

  Successfully raised net proceeds of $242.2 million through its at-the-market (ATM) offering facility, with $112.2 million in Q4 2025 and an additional $130.0 million in Q1 2026.

• Extended Cash Runway

  Pro forma cash, cash equivalents, and marketable securities of $716.0 million (including Q1 2026 ATM proceeds) are anticipated to fund operations into the second half of 2027.

• Imminent Phase 3 Data Readout

  Topline data from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS) is expected in the first half of March 2026, representing a critical near-term catalyst.

auto_awesomeAnalysis

Xenon Pharmaceuticals reported its full-year 2025 financial results, showing a significant increase in R&D expenses and net loss, which is typical for a biotech company advancing multiple late-stage clinical programs. Crucially, the company successfully raised $242.2 million through its at-the-market (ATM) offering facility, including $130.0 million in Q1 2026, extending its cash runway into the second half of 2027. This substantial capital raise provides financial stability to support its extensive clinical pipeline. The filing also highlights a major near-term catalyst: topline data from the Phase 3 X-TOLE2 study for azetukalner in focal onset seizures is expected in the first half of March 2026, with an anticipated NDA submission in the second half of 2026. Investors will closely watch these upcoming clinical readouts and regulatory progress.